Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MCF12A | NM | Basal B | Trastuzumab | HER2 | ErbB | 0.0115 | uM | 10061.123 | 1.0199 | 1.0208 | 1.9064 | |
| MCF12A | NM | Basal B | Trastuzumab | HER2 | ErbB | 0.0576 | uM | 10061.123 | 1.0263 | 1.0275 | 1.9064 | |
| MCF12A | NM | Basal B | Trastuzumab | HER2 | ErbB | 0.288 | uM | 10061.123 | 1.0119 | 1.0124 | 1.9064 | |
| MCF12A | NM | Basal B | Trastuzumab | HER2 | ErbB | 1.44 | uM | 10061.123 | 1.0222 | 1.0231 | 1.9064 | |
| MCF12A | NM | Basal B | Trastuzumab | HER2 | ErbB | 7.2 | uM | 10061.123 | 0.8707 | 0.8599 | 1.9064 | |
| MCF7 | HR+ | Luminal | Trastuzumab | HER2 | ErbB | 0.0000184 | uM | 9583.026 | 1.0054 | 1.0085 | 1.2731 | |
| MCF7 | HR+ | Luminal | Trastuzumab | HER2 | ErbB | 0.0000922 | uM | 9583.026 | 1.0002 | 1.0003 | 1.2731 | |
| MCF7 | HR+ | Luminal | Trastuzumab | HER2 | ErbB | 0.000461 | uM | 9583.026 | 0.9718 | 0.9556 | 1.2731 | |
| MCF7 | HR+ | Luminal | Trastuzumab | HER2 | ErbB | 0.0023 | uM | 9583.026 | 0.9916 | 0.9868 | 1.2731 | |
| MCF7 | HR+ | Luminal | Trastuzumab | HER2 | ErbB | 0.0115 | uM | 9583.026 | 0.9448 | 0.9127 | 1.2731 | |
| MCF7 | HR+ | Luminal | Trastuzumab | HER2 | ErbB | 0.0576 | uM | 9583.026 | 1.0035 | 1.0055 | 1.2731 | |
| MCF7 | HR+ | Luminal | Trastuzumab | HER2 | ErbB | 0.288 | uM | 9583.026 | 0.9823 | 0.9722 | 1.2731 | |
| MCF7 | HR+ | Luminal | Trastuzumab | HER2 | ErbB | 1.44 | uM | 9583.026 | 0.9734 | 0.9580 | 1.2731 | |
| MCF7 | HR+ | Luminal | Trastuzumab | HER2 | ErbB | 7.2 | uM | 9583.026 | 0.8776 | 0.8051 | 1.2731 | |
| MDA-MB-134-VI | HR+ | Luminal | Trastuzumab | HER2 | ErbB | 0.0000184 | uM | 10077.026 | 1.1832 | 2.0461 | 0.3999 | |
| MDA-MB-134-VI | HR+ | Luminal | Trastuzumab | HER2 | ErbB | 0.0000922 | uM | 10077.026 | 1.1295 | 1.7121 | 0.3999 | |
| MDA-MB-134-VI | HR+ | Luminal | Trastuzumab | HER2 | ErbB | 0.000461 | uM | 10077.026 | 1.2687 | 2.6262 | 0.3999 | |
| MDA-MB-134-VI | HR+ | Luminal | Trastuzumab | HER2 | ErbB | 0.0023 | uM | 10077.026 | 1.0469 | 1.2427 | 0.3999 | |
| MDA-MB-134-VI | HR+ | Luminal | Trastuzumab | HER2 | ErbB | 0.0115 | uM | 10077.026 | 1.1823 | 2.0402 | 0.3999 | |
| MDA-MB-134-VI | HR+ | Luminal | Trastuzumab | HER2 | ErbB | 0.0576 | uM | 10077.026 | 1.1474 | 1.8209 | 0.3999 | |
| MDA-MB-134-VI | HR+ | Luminal | Trastuzumab | HER2 | ErbB | 0.288 | uM | 10077.026 | 1.1712 | 1.9695 | 0.3999 | |
| MDA-MB-134-VI | HR+ | Luminal | Trastuzumab | HER2 | ErbB | 1.44 | uM | 10077.026 | 1.1639 | 1.9229 | 0.3999 | |
| MDA-MB-134-VI | HR+ | Luminal | Trastuzumab | HER2 | ErbB | 7.2 | uM | 10077.026 | 0.8823 | 0.4622 | 0.3999 | |
| MDA-MB-361 | HER2amp | Luminal | Trastuzumab | HER2 | ErbB | 0.0000184 | uM | 9648.026 | 0.9918 | 0.9768 | 0.7065 | |
| MDA-MB-361 | HER2amp | Luminal | Trastuzumab | HER2 | ErbB | 0.0000922 | uM | 9648.026 | 0.9821 | 0.9495 | 0.7065 |